Received Aug 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 4 | — | — |
No additional AE; HCP called and reported inadvertent administration of a total of 4 doses of GARDASIL 9. Adult patient received a dose of GARDASIL 9 on 19SEP2024, 06NOV2024, 19MAR2025, and 07AUG2025.; This spontaneous report was received from a Physician on 07-Aug-2025 and refers to a 37 year old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 19-Sep-2024,06-Nov-2024, and 19-Mar-2025, the patient was vaccinated with a first, second, and third dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL9),(dose, indication, expiration date, and lot # were not reported) for prophylaxis And 07-Aug-2025, the patient was inadvertently vaccinated with a fourth dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL9) (dose, indication, expiration date, and lot # were not reported) for prophylaxis (Extra dose administered). No additional adverse event or PQC reported.